近日有机构在研究报告中表示,继续对医药板块在2025年走出反转行情抱有强烈信心。创新药建议关注泛癌种潜力的双/多抗药物,解决未满足临床需求的慢病药,持续关注ADC、双抗/多抗、小核酸赛道等的投资机会。重点标的包括信达生物、康方生物、科伦博泰、恒瑞医药、诺诚健华、华东医药等。其中根据相关数据显示,双特异性抗体药物市场正迎来爆发式增长,2024年全球双抗药物市场规模已达126亿美元,预计2030年将...
Source Link近日有机构在研究报告中表示,继续对医药板块在2025年走出反转行情抱有强烈信心。创新药建议关注泛癌种潜力的双/多抗药物,解决未满足临床需求的慢病药,持续关注ADC、双抗/多抗、小核酸赛道等的投资机会。重点标的包括信达生物、康方生物、科伦博泰、恒瑞医药、诺诚健华、华东医药等。其中根据相关数据显示,双特异性抗体药物市场正迎来爆发式增长,2024年全球双抗药物市场规模已达126亿美元,预计2030年将...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.